Cargando…

Integrase inhibitors versus efavirenz combination antiretroviral therapies for TB/HIV coinfection: a meta-analysis of randomized controlled trials

BACKGROUND: Integrase inhibitors (INIs)-based antiretroviral therapies (ART) are more recommended than efavirenz (EFV)-based ART for people living with HIV/AIDS (PLWHA). Yet, the advantage of integrase inhibitors in treating TB/HIV coinfection is uncertain. Therefore, the objective of this systemati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shu, Yuanlu, Deng, Ziwei, Wang, Hongqiang, Chen, Yi, Yuan, Lijialong, Deng, Ye, Tu, Xiaojun, Zhao, Xiang, Shi, Zhihua, Huang, Minjiang, Qiu, Chengfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088572/ https://www.ncbi.nlm.nih.gov/pubmed/33933131 http://dx.doi.org/10.1186/s12981-021-00348-w

Ejemplares similares

Elevated circulating PCSK9 level is associated with 28-day mortality in patients with sepsis: a prospective cohort study
por: Shu, Yuanlu, et al.
Publicado: (2023)

Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIV
por: Sundell, Jesper, et al.
Publicado: (2021)

HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?
por: Vogel, Martin, et al.
Publicado: (2009)

Risk of Cardiovascular Events Among Patients Initiating Efavirenz-Containing Versus Efavirenz-Free Antiretroviral Regimens
por: Rosenblatt, Lisa, et al.
Publicado: (2016)

Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials
por: Qiu, Chengfeng, et al.
Publicado: (2019)

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
por: Song, Ivy, et al.
Publicado: (2014)

Weight Gain After Switch from Efavirenz-Based to Integrase Inhibitor-Based Regimens
por: Norwood, Jamison, et al.
Publicado: (2017)

HIV-TB coinfection: Clinico-epidemiological determinants at an antiretroviral therapy center in Southern India
por: Kamath, Ramachandra, et al.
Publicado: (2013)

Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy
por: Huang, Sung-Hsi, et al.
Publicado: (2017)

Reply to “At the crossroads between early or delayed antiretroviral therapy initiation during TB/HIV coinfection”
por: Saraceni, Valeria, et al.
Publicado: (2014)

Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship
por: Bhatt, Nilesh B., et al.
Publicado: (2015)

Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
por: Deng, Lisi, et al.
Publicado: (2022)

‘Covering the tail’ after stopping efavirenz-based antiretroviral therapy
por: Maartens, Gary
Publicado: (2020)

Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study
por: Sinha, Sanjeev, et al.
Publicado: (2013)

Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz
por: Larru, Beatriz, et al.
Publicado: (2014)

Acute Liver Failure among Patients on Efavirenz-Based Antiretroviral Therapy
por: Segamwenge, Innocent Lule, et al.
Publicado: (2018)

Altered Gut Microbiome under Antiretroviral Therapy: Impact of Efavirenz and Zidovudine
por: Ray, Shilpa, et al.
Publicado: (2020)

Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study
por: Sinha, Sanjeev, et al.
Publicado: (2017)

Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania
por: Sungi, Selemani Saidi, et al.
Publicado: (2018)

Resistance to new antiretrovirals (ETV, anti-integrases, entry inhibitors)
por: Ceccherini-Silberstein, Francesca
Publicado: (2010)

Lopinavir/r + Efavirenz combination as a potent NRTI sparing antiretroviral therapy
por: Henrivaux, Philippe, et al.
Publicado: (2010)

Efavirenz Conceptions and Regimen Management in a Prospective Cohort of Women on Antiretroviral Therapy
por: Schwartz, Sheree, et al.
Publicado: (2012)

Drug resistance after cessation of efavirenz-based antiretroviral treatment started in pregnancy
por: Ajibola, Globahan, et al.
Publicado: (2020)

Pregnancy outcomes following exposure to efavirenz based antiretroviral therapy in indian women
por: Mishra, Rajesh Kumar, et al.
Publicado: (2020)

TB AND COVID-19 COINFECTION: A CASE SERIES
por: CÎRJALIU, R.-E., et al.
Publicado: (2022)

Pharmacokinetics of Efavirenz 600mg in Combination with Rifampicin in Chinese HIV/TB Co-Infection Patients
por: Wang, Tongtong, et al.
Publicado: (2023)

Circulating prekallikrein levels are correlated with lipid levels in the chinese population: a cross-sectional study
por: Shu, Yuanlu, et al.
Publicado: (2023)

Impact of Raltegravir or Efavirenz on Cell-Associated Human Immunodeficiency Virus-1 (HIV-1) Deoxyribonucleic Acid and Systemic Inflammation in HIV-1/Tuberculosis Coinfected Adults Initiating Antiretroviral Therapy
por: Delagreverie, Héloïse M, et al.
Publicado: (2020)

Case Report: Reversal of Integrase Inhibitor– and Tenofovir Alafenamide–Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF
por: Pohlman, F Will, et al.
Publicado: (2021)

Effect of Gender on Clinical Presentation of Tuberculosis (TB) and Age-Specific Risk of TB, and TB-Human Immunodeficiency Virus Coinfection
por: Humayun, Maheen, et al.
Publicado: (2022)

Kinetics of Microbial Translocation Markers in Patients on Efavirenz or Lopinavir/r Based Antiretroviral Therapy
por: Vesterbacka, Jan, et al.
Publicado: (2013)

Antiretroviral Treatment with Efavirenz Disrupts the Blood-Brain Barrier Integrity and Increases Stroke Severity
por: Bertrand, Luc, et al.
Publicado: (2016)

Concentration-Response Relationships of Dolutegravir and Efavirenz with Weight Change After Starting Antiretroviral Therapy
por: Griesel, Rulan, et al.
Publicado: (2022)

Antiretroviral drugs efavirenz, dolutegravir and bictegravir dysregulate blood-brain barrier integrity and function
por: Huang, Chang, et al.
Publicado: (2023)

HIV integrase variability and genetic barrier in antiretroviral naïve and experienced patients
por: Piralla, Antonio, et al.
Publicado: (2011)

HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure
por: van Hal, Sebastiaan J, et al.
Publicado: (2009)

Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients
por: Yimer, Getnet, et al.
Publicado: (2011)

Elevated Notch ligands in serum are associated with HIV/TB coinfection
por: Bermick, Jennifer R., et al.
Publicado: (2021)

The Medication Experience of TB/HIV Coinfected Patients: Qualitative Study
por: de Resende, Natália Helena, et al.
Publicado: (2022)

Treatment Outcomes of Dolutegravir- Versus Efavirenz-Based Highly Active Antiretroviral Therapy Regimens Among Treatment-Naive People Living With HIV
por: Mahale, Prarthana R, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_go6b525u7b3huqea4vr2543jhg